Optimality, sample size, and power calculations for the sequential parallel comparison design
- 29 July 2011
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 30 (23) , 2793-2803
Abstract
The sequential parallel comparison design (SPCD) has been proposed to increase the likelihood of success of clinical trials in therapeutic areas where high‐placebo response is a concern. The trial is run in two stages, and subjects are randomized into three groups: (i) placebo in both stages; (ii) placebo in the first stage and drug in the second stage; and (iii) drug in both stages. We consider the case of binary response data (response/no response). In the SPCD, all first‐stage and second‐stage data from placebo subjects who failed to respond in the first stage of the trial are utilized in the efficacy analysis. We develop 1 and 2 degree of freedom score tests for treatment effect in the SPCD. We give formulae for asymptotic power and for sample size computations and evaluate their accuracy via simulation studies. We compute the optimal allocation ratio between drug and placebo in stage 1 for the SPCD to determine from a theoretical viewpoint whether a single‐stage design, a two‐stage design with placebo only in the first stage, or a two‐stage design is the best design for a given set of response rates. As response rates are not known before the trial, a two‐stage approach with allocation to active drug in both stages is a robust design choice. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 12 references indexed in Scilit:
- Comparison of Test Statistics for the Sequential Parallel DesignStatistics in Biopharmaceutical Research, 2010
- Design and Analysis of Crossover Trials for Absorbing Binary EndpointsBiometrics, 2009
- Enrichment Design2007
- An examination of the efficiency of the sequential parallel design in psychiatric clinical trialsClinical Trials, 2007
- Duloxetine in the Treatment of DepressionJournal of Clinical Psychopharmacology, 2004
- ErratumPsychotherapy and Psychosomatics, 2004
- The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design ApproachPsychotherapy and Psychosomatics, 2003
- Placebo Response and Antidepressant Clinical Trial OutcomeJournal of Nervous & Mental Disease, 2003
- Are placebo run ins justified?BMJ, 1997
- Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?Neuropsychopharmacology, 1994